Cogent Biosciences (COGT) Amortization of Deferred Charges (2025 - 2026)

Cogent Biosciences (COGT) has reported Amortization of Deferred Charges for 6 consecutive years, with $278000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 44.18% year-over-year to $278000.0; the TTM figure through Mar 2026 stood at $1.8 million (down 6.88% YoY), while the FY2025 annual figure was $2.0 million, up 6.21% from the prior year.
• Amortization of Deferred Charges fell to $278000.0 in Q1 2026 per COGT's latest filing, from $1.7 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $3.5 million in Q3 2022 and bottomed at -$435000.0 in Q2 2025.
• Historically, Amortization of Deferred Charges has averaged $620705.9 across 5 years, with a median of $477000.0 in 2024.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 641.42% — and 2025, when it tumbled 191.77%.
• Cogent Biosciences' Amortization of Deferred Charges stood at $517000.0 in 2022, then slumped by 62.09% to $196000.0 in 2023, then surged by 146.43% to $483000.0 in 2024, then jumped by 242.86% to $1.7 million in 2025, then plunged by 83.21% to $278000.0 in 2026.
• Business Quant data shows COGT's Amortization of Deferred Charges at $278000.0 in Q1 2026, $1.7 million in Q4 2025, and $300000.0 in Q3 2025.